considerations for risk-adapted therapy in lower-risk mds
Published 11 months ago • 64 plays • Length 1:50Download video MP4
Download video MP3
Similar videos
-
1:34
managing adverse events with novel therapies in lower-risk mds
-
1:20
the current standard of care for patients with lower-risk mds
-
1:54
risk-adapted therapy: three-day versus five-day oral decitabine in patients with mds
-
1:18
the importance risk stratification to enable risk-adapted therapy in mds & cmml
-
1:59
the role of inflammatory signaling pathways in lower-risk mds
-
11:53
the optimal treatment of lower risk mds
-
3:06
the role of chronic inflammation in lower-risk mds and future therapeutic strategies
-
2:00
the role of fedratinib in 2024 and beyond
-
0:52
the need to incorporate disease-modifying drugs in lower-risk mds
-
0:56
the promise of luspatercept for the treatment of lower-risk mds
-
11:33
treatment algorithm for low-risk mds
-
1:02
emerging treatment options for lower- and higher-risk mds and ongoing trials
-
2:12
improving the treatment of low-risk mds: luspatercept, treatment sequencing & disease classification
-
1:48
the impact of esas in lower-risk mds
-
3:38
a new set of treatment options for low-risk mds
-
1:02
update on treatments for high- and low-risk mds
-
2:25
master final analysis: quadruplet induction therapy, asct & mrd-adapted treatment cessation in ndmm
-
2:37
esas for the management of lower-risk mds
-
4:12
novel therapies in low-risk mds